Drug class
Recombinant human acid sphingomyelinase; enzyme replacement therapy biologic
Mechanism of action
Provides exogenous acid sphingomyelinase that hydrolyses sphingomyelin to ceramide and phosphorylcholine in lysosomes, reducing sphingomyelin accumulation in peripheral organs.
General use cases
- Enzyme replacement therapy for non-central-nervous-system manifestations of acid sphingomyelinase deficiency (ASMD) in adults and paediatric patients; it does not treat CNS manifestations because the enzyme does not cross the blood-brain barrier
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
